CANCER

A new age of per­son­al­ized can­cer care begun with the intro­duc­tion of the “Liq­uid Biopsy” concept. Novel blood test detect cancer cells, tumor-associated cells, and immune cells in the cir­cu­la­tion and pro­vid­e a non-​invasive real-time pic­ture of a patient’s malignant disease. The tests enable pos­si­ble post-​therapeutic sur­veil­lance of recurrence.

Blood-based biopsy diag­nos­tics is a mix of high-​tech tech­nol­ogy and cut­ting edge med­ical pro­ce­dures, and offers new ways for selec­tion of the right drug for the right patient at the right time — all through a sim­ple blood draw.

CK-19 Kits

Cytokeratin 19 (CK-19) is a general marker of epithelial cells that is strongly expressed in epithelial but not in mesenchymal cells. Increased expression is seen during epithelial embryogenesis, tissue regeneration, tissue repair, tissue development, and carcinogenesis. CK-19 has been extensively studied as a potential marker for the detection of circulating tumor cells (CTC) in a variety of epithelial cancers. It is a cytoskeletal component present in normal and cancerous epithelial cells. It is expressed in 90% of invasive breast cancer tissue and thus, has been extensively used for the detection of breast cancer cells in mesenchymal tissues. It is probably the most sensitive and reliable tumor marker for the detection of CTC in patients with breast cancer.

The list of innovative products comprises RT-qPCR-based tests for the quantification of CK-19 mRNA in RNA samples.

Products Unit size REF IFU Brochure Note
CK-19 Kit 24 tests OL1011024 not for in vitro diagnostic use

coming soon

CK-19 Kit LC 24 tests OL1010024 PDF not for in vitro diagnostic use
CK-19 Kit LC 48 tests OL1010048 PDF not for in vitro diagnostic use
CK-19 Kit LC 96 tests OL1010096 PDF not for in vitro diagnostic use
CK-19 Kit CE-IVD 24 tests OL1010124    coming soon
CC CK-19 610-670 Kit 1 run OL0010006 PDF not for in vitro diagnostic use
CC CK-19 610-670 Kit CE-IVD 1 run OL0010106   coming soon

CRC IF Kits

Detecting Rare Cells in blood and other body fluids can be a real challenge. OncoLab provides research tools that make hunting for rare cells, such as circulating tumor cells (CTC),  circulating endothelial cells (CEC), or circulating stromal cells (CSC) a simple diagnostic test.

OncoLab's Circulating Rare Cell (CRC) tests are based on fluorescent immunostaining of rare cells after enrichment from blood samples. State-of-the-art biomarkers coupled with enhanced scanning optical systems powered by artificial intelligence enable convenient and efficient research of CRC.

The list of products comprises special blood collection tubes, tools and reagents for cell purification, proprietary immunofluorescent cocktails for staining (IF), tools and general use reagents for preparing cytology slides, microscope imaging, and image analysis.

Products Unit size REF IFU Brochure Note
nPACTM CTC IF Kit 12 rxn OL5010012 PDF not for in vitro diagnostic use
nPACTM CSC IF Kit 12 rxn OL5080012 PDF not for in vitro diagnostic use
nPACTM CSC/CEC IF Kit 12 rxn OL5070012 PDF not for in vitro diagnostic use
Blood Collection Kit CE-IVD 12 samples OL6010112
CRC IF Materials Kit 12 samples OL5090012 not for in vitro diagnostic use
 

nCyte DxTM Advanced Optical Scanner

incl. nAble® Software

 

1 instrument

 

OL90100

PDF not for in vitro diagnostic use

In the pipeline

Several tests for PCR-based detection and molecular characterization of circulating tumor cells (CTC) are under development.

The list of future products comprises multi-marker tests for breast cancer, lung cancer, ovarian cancer, cervical cancer, endometrial cancer, and neuroendocrine tumors. Tools and reagents for collecting and stabilizing patients' blood samples, enrichment of circulating rare cells (CRC), or depletion of unwanted cells are in the pipeline as well.